Physician profile
Mark Kandary
NPI 1104277235
$523.42
in general payments reported to CMS, 2019-2025
11 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.43 · 2021: $108 · 2022: $27.44 · 2023: $182 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $317 · Education: $18.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $317.14 |
| Education | $18.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Outset Medical INC | $139.18 | 2023 | |
| Aurinia Pharma U.S., INC. | $108.47 | 2021 | |
| Amgen INC. | $70.49 | 2022-2025 | Tavneos |
| Boston Scientific Corporation | $51.43 | 2019 | |
| Calliditas Therapeutics US INC. | $30.43 | 2025 | Tarpeyo |
| Ascendis Pharma Endocrinology INC | $25.91 | 2025 | Yorvipath |
| Astrazeneca Pharmaceuticals LP | $25.60 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $21.29 | 2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $18.94 | 2025 | Rayaldee |
| Lilly USA, LLC | $16.92 | 2023 | Mounjaro |
| Travere Therapeutics, INC. | $14.76 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kandary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.